Adagrasib is the second approved KRAS inhibitor for NSCLC after sotorasib, which was approved in 2021 (Kayki-Mutlu et al. 2022); adagrasib was found to be superior to sotorasib in the objective response rate (Tian and Yang 2022). This evidence concerns the gene KRAS and non-small cell lung carcinoma.